liminatuspharma.com - הכנסה לפני ניכוי ריבית, מסים ופחת LIMN

Liminatus Pharma is investing in R&D for gastrointestinal tumor vaccines while the market awaits the start of clinical trials. The company's absolute operating profit in cash demonstrates real cash flow, where the value of 0.00 reflects this status. Recruiting leading oncologists to develop CAR-T therapy provides the scientific foundation for the issuer's future success.

Diversifying its cell therapy portfolio for solid tumors allows Liminatus Pharma (LIMN) to scale patient reach while minimizing the specific risks associated with oncological development. This metric measures the actual cash flow from core operations before depreciation and taxes, helping investors assess the fundamental stability of the business by tracking absolute EBITDA deviations to avoid overpaying for the asset.